Mr. Ahmad Doroudian reports
BETTERLIFE PHARMA ANNOUNCES STOCK OPTION GRANT
Betterlife Pharma Inc. has agreed to grant stock options to purchase 300,000 common shares in the capital of the company to a member of its scientific advisory board.
The options are exercisable at a price of 25 cents per common share, will have a term of 10 years and will vest quarterly over 24 months from the date of grant. The options were granted pursuant to the company's amended and restated long-term incentive plan dated Aug. 27, 2026, as amended on Nov. 5, 2026. The options are subject to the terms and conditions prescribed by the plan, the Canadian Securities Exchange and applicable securities laws.
About Betterlife Pharma Inc.
Betterlife is an emerging biotechnology company primarily focused on developing and commercializing BETR-001 to treat various neurological disorders, such as chronic cluster headache and chronic migraine.
We seek Safe Harbor.
© 2026 Canjex Publishing Ltd. All rights reserved.